242 related articles for article (PubMed ID: 30281216)
1. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
4. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Lv C; Liu X; Zheng Q; Chen H; Yang X; Zhong J; Wang Y; Duan J; Wang Z; Bai H; Wu M; Zhao J; Wang J; Wang Z; An T; Zhuo M
Thorac Cancer; 2018 Sep; 9(9):1166-1173. PubMed ID: 30058109
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
7. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
Enomoto Y; Inui N; Imokawa S; Karayama M; Hasegawa H; Ozawa Y; Matsui T; Yokomura K; Suda T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):499-505. PubMed ID: 26134440
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
Lycan TW; Pardee TS; Petty WJ; Bonomi M; Alistar A; Lamar ZS; Isom S; Chan MD; Miller AA; Ruiz J
PLoS One; 2016; 11(10):e0164244. PubMed ID: 27732654
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
12. Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
Sone H; Igawa S; Kasajima M; Ishihara M; Hiyoshi Y; Hosotani S; Ohe S; Ito H; Kaizuka N; Manaka H; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Thorac Cancer; 2018 Oct; 9(10):1279-1284. PubMed ID: 30126051
[TBL] [Abstract][Full Text] [Related]
13. Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs.
Park YH; Chung CU; Park BM; Park MR; Park DI; Moon JY; Park HS; Kim JH; Jung SS; Kim JO; Kim SY; Lee JE
Can Respir J; 2016; 2016():3576201. PubMed ID: 28018128
[No Abstract] [Full Text] [Related]
14. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J; Zhao X; Schell M; Sullivan DM
Oncologist; 2016 Oct; 21(10):1163-1164. PubMed ID: 27694157
[TBL] [Abstract][Full Text] [Related]
15. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
17. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
Ardizzoni A; Tiseo M; Boni L
Eur J Cancer; 2014 Sep; 50(13):2211-8. PubMed ID: 24981975
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
Kang JH; Lee KH; Kim DW; Kim SW; Kim HR; Kim JH; Choi JH; An HJ; Kim JS; Jang JS; Kim BS; Kim HT
Br J Cancer; 2021 Feb; 124(4):713-720. PubMed ID: 33191408
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
[TBL] [Abstract][Full Text] [Related]
20. Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.
Garst J; Buller R; Lane S; Crawford J
Clin Lung Cancer; 2005 Nov; 7(3):190-6. PubMed ID: 16354314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
